High throughput proteomic strategies for identifying tumour-associated antigens.
about
Early lung cancer diagnosis by biosensors.Serum anti-BPAG1 auto-antibody is a novel marker for human melanomaProteome serological determination of tumor-associated antigens in melanoma.A systems immunology approach to the host-tumor interaction: large-scale patterns of natural autoantibodies distinguish healthy and tumor-bearing mice.Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphomaImmunoscreening of the extracellular proteome of colorectal cancer cells.Simple screening method for autoantigen proteins using the N-terminal biotinylated protein library produced by wheat cell-free synthesis.Tumor antigen analysis in neuroblastoma by serological interrogation of bioinformatic data.Tumour auto-antibody screening: performance of protein microarrays using SEREX derived antigens.A broadly applicable approach to T cell epitope identification: application to improving tumor associated epitopes and identifying epitopes in complex pathogens.Tumor-associated autoantibodies as diagnostic and prognostic biomarkers.Preliminary study of thyroid and colon cancers-associated antigens and their cognate autoantibodies as potential cancer biomarkers.Hypoxia integration in the serological proteome analysis unmasks tumor antigens and fosters the identification of anti-phospho-eEF2 antibodies as potential cancer biomarkers.Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of conceptAntibody profiling with protein antigen microarrays in early stage cancer.State of the art in tumor antigen and biomarker discovery.An approach to the identification of T cell epitopes in the genomic era: application to Francisella tularensisAntibody technology in proteomics.Specificity in cancer immunotherapy.Microarray methods for protein biomarker detectionIdentifying autoantibody signatures in cancer: a promising challenge.Serum autoantibodies as biomarkers for early cancer detection.Targeted drug delivery for cancer therapy: the other side of antibodies.New targets for the immunotherapy of colon cancer-does reactive disease hold the answer?Systems vaccinology for cancer vaccine development.Immunoseroproteomic Profiling in African American Men with Prostate Cancer: Evidence for an Autoantibody Response to Glycolysis and Plasminogen-Associated Proteins.Immuno-proteomics: Development of a novel reagent for separating antibodies from their target proteins.Using proteomics to identify preprocedural risk factors for contrast induced nephropathy.Gold-loaded nanoporous iron oxide nanocubes: a novel dispersible capture agent for tumor-associated autoantibody analysis in serum.In-depth quantitative proteomics for pancreatic cancer biomarker discovery.[Autoantibodies as the early diagnostic biomarkers for lung cancer].
P2860
Q30449799-3B361EE2-EC4F-42F5-846C-BC49A2215004Q30982790-404D0343-5041-47AF-BC96-EFC2ACB813C1Q33432732-4CEC021C-A741-44DC-989E-1BD4B7047625Q33474793-4F20921A-923D-4967-8FBA-5E1447BC3988Q33519571-C49208EC-6BA6-4BD3-B4E1-DA4DCEBD7A8BQ33534464-32DAEED1-80A0-4F9A-8234-E9E81F7B6267Q33615026-C8F446F5-0AC8-4391-89A6-C468487857FEQ33662452-1914944A-6BC4-4D05-B717-3129E2317947Q33747137-BBB54E5D-80DE-4323-B999-20E6FEE43468Q34004266-0F651B93-E77F-430A-BA20-DF3E19BA9541Q34049184-4571BFCB-037F-420B-8C57-068C9200708FQ34276070-61C85DAF-6761-4BEC-95BC-C8180DC4CEC4Q35018525-D64FD0E0-6CCF-4AE4-82AA-285D7CF74F17Q35193892-989909EF-B9E4-4179-BF91-366C110E3A2DQ36682206-D4D0CA25-99FB-4BE7-B005-CA20FFD152DFQ37132800-679D955E-5B40-4AAF-A1EB-97A002626422Q37158563-C3E5E9C6-F16C-4614-945A-91EF0488CB85Q37202448-DFEECC34-B325-4EB0-86ED-2035B599474DQ37236636-5A443B6D-39D9-4E0A-9C70-CC0E11D32297Q37335033-6F2ED8EB-25CB-475B-9E2C-C955F0BA173BQ37579900-7E5FBE91-2168-448F-9198-5742D77134EDQ37622471-EFE09784-7949-415C-B2B4-FBD7A95E74BDQ38058816-A4419D58-28ED-43E0-989E-8DFAA62A7995Q38089480-C68D65C8-806C-4173-BE61-6973E41AD6F8Q38207141-5805C370-9555-47B5-B450-78CBFB42A3ADQ38386585-1AF7EED4-71B8-4776-BAF3-DFF2F013A915Q41104625-78F290E2-C744-47C0-A2DA-21B5019E9E05Q43251879-E9A92490-D890-4C2D-9CD3-88FD7AD5B30DQ48753963-C213BEC9-E3B8-4F96-B2CD-F9F2438B9494Q53531433-AA7906B2-DD42-4392-A957-EFE08B99C00CQ55436520-68FED0F8-8122-473D-A96C-960E0B7CFA00
P2860
High throughput proteomic strategies for identifying tumour-associated antigens.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
High throughput proteomic strategies for identifying tumour-associated antigens.
@ast
High throughput proteomic strategies for identifying tumour-associated antigens.
@en
High throughput proteomic strategies for identifying tumour-associated antigens.
@nl
type
label
High throughput proteomic strategies for identifying tumour-associated antigens.
@ast
High throughput proteomic strategies for identifying tumour-associated antigens.
@en
High throughput proteomic strategies for identifying tumour-associated antigens.
@nl
prefLabel
High throughput proteomic strategies for identifying tumour-associated antigens.
@ast
High throughput proteomic strategies for identifying tumour-associated antigens.
@en
High throughput proteomic strategies for identifying tumour-associated antigens.
@nl
P1433
P1476
High throughput proteomic strategies for identifying tumour-associated antigens.
@en
P2093
C Geeth Gunawardana
P304
P356
10.1016/J.CANLET.2007.01.002
P407
P577
2007-02-15T00:00:00Z